Skip to main content
. 2020 Sep 16;28(11):2320–2339. doi: 10.1016/j.ymthe.2020.09.015

Table 1.

Selected Published CAR T Cell Clinical Studies for Solid Tumors and Brain Tumors

Antigen Diagnosis Signaling Domain Vector T Cell Product IL-2 after T Cells Comment References
Intravenous Administration, No Lymphodepleting Chemotherapy
FRα OVCA ζ RV ATCsa Y 14/14 NR 21
CAIX RCC ζ RV ATCs N 12/12 NR; on target/off cancer toxicity—bile ducts 19,20
CD171 NB ζ Plasmid T cell clone N 1/6 PR 83
EGFRvIII HGG 4-1BB LV ATCs N 1/10 SD 17
GD2 NB ζ RV ATCs, VSTs N 3/11 CR 81,82
HER2 sarcoma CD28ζ RV ATCs N 4/17 SD 23
HER2 HGG CD28ζ RV VSTs N 3/17 SD 26
Mesothelin PCA 41BBζ mRNA ATCs N 2/6 SD 80
Intravenous Administration after Lymphodepleting Chemotherapy
CD133 HCC, PCA, CRC 41BBζ LV ATCs N 3/23 PR, 14/23 SD 24
CEACAM5 CRC, PDCA, stomach, esophagus ζ RV ATCs Y 7/14 SD; on target/off cancer toxicity—lung 25
EGFR PCA 41BBζ LV ATCs N 4/16 PR, 8/16 SD, 2/16 NE 86
EGFRvIII HGG CD28.41BBζ RV ATCs Y 17/18 NR, 1/18 NE due to TRMb 16
GD2 NB CD28.OX40ζ RVc ATCs N 5/11 SD 87
GPC3 HCC CD28ζ LV ATCs N 2/13 PR, 1/13 SD, 4/13 NE 88
HER2 CRC CD28.41BBζ LV ATCs Y 1/1 TRMb; on target/off cancer toxicity—lung 18
HER2 sarcoma CD28ζ RV ATCs N 1/10 CR; 3/10 SD 89,90
Mesothelin MPM, PCA, OVCA 41BBζ LV ATCs N 11/15d SD 91
PSMA prostate ζ RV ATCs Y 2/5 PR 71
ROR1 TNBC, NSCLC 41BBζ LV ATCs N 4/6 mixed response;
1/6 SD; 1/6 not reported		 72
VEGF-R2 metastatic CA – RV ATCs Y 1/23 PR e
Intravenous Administration after Allotransplant
GD2 NB ζ RV VSTs N 3/3 PD f
Locoregional Administration
B7-H3 meningioma 41BBζ LV ATCs N 1/1 evidence of ALV 73
IL-13Rα2 HGG ζ plasmid T cell clone N 1/3 tumor necrosis 74
IL-13Rα2 HGG ζ plasmid T cell clonea N imaging study; outcome not reported 75
IL-13Rα2 HGG 41BBζ LV ATCs N 1/1 CR 22
Mesothelin MPM, lung CA, breast CA CD28ζ RVc ATCs N 2/21g CR, 5/21 PR, 4/21 SD 76
MUC1 SVA 41BBζ or CD28ζ LVh ATCs N 1/1 tumor necrosis 92

ALV, antigen loss variant; ATC, activated T cell; CA, cancer; CR, complete response; CRC, colorectal cancer; HCC, hepatocellular carcinoma; HGG, high-grade glioma; LV, lentivirus; MPM, malignant pleural mesothelioma; N, no; NB, neuroblastoma; NE, not evaluable; NR, no response; OVCA, ovarian cancer; PCA, pancreatic adenocarcinoma; PR, partial response; RCC, renal cell carcinoma; RV, retrovirus; SD, stable disease; SVA, seminal vesicle adenocarcinoma; VST, virus-specific T cell; Y, yes.

a

Several patients received allogeneic cell products.

b

Pulmonary complications.

c

CAR vector also encoded inducible caspase-9.

d

6 of 15 patients received lymphodepleting chemotherapy.

e

ClinicalTrials.gov: NCT01218867.

f

ClinicalTrials.gov: NCT01460901.

g

18 of 21 patients received lymphodepleting chemotherapy and 13 of 21 patients received pembrolizumab.

h

41BBζ CAR vector also encoded IL-12.